Lessons From Africa: The Importance of Measuring Plasma Renin and Aldosterone in Resistant Hypertension

Canadian Journal of Cardiology

Volumn 28, Issue 3, 2012, Pages 254-257

  Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; COLLAGEN; ELASTIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; RENIN;

AFRICA; ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; EDITORIAL; FLUID RETENTION; GENETIC POLYMORPHISM; HUMAN; HYPOKALEMIA; RESISTANT HYPERTENSION;

AFRICA; AFRICAN AMERICANS; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; ONTARIO; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84860915624     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.11.010     Document Type: Editorial

References (46)

1. Weder A.B., Gleiberman L., Sachdeva A. Whites excrete a water load more rapidly than blacks. Hypertension 2009, 53:715-718.
2. Lindhorst J., Alexander N., Blignaut J., Rayner B. Differences in hypertension between blacks and whites: an overview. Cardiovasc J Afr 2007, 18:241-247.
3. Opie L.H., Seedat Y.K. Hypertension in sub-Saharan African populations. Circulation 2005, 112:3562-3568.
4. Spence J.D. Physiologic tailoring of treatment in resistant hypertension. Current Cardiology Rev 2010, 6:213-219.
5. Howard G., Prineas R., Moy C., et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke 2006, 37:1171-1178.
6. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486.
7. Markus H.S., Khan U., Birns J., et al. Differences in stroke subtypes between black and white patients with stroke: the South London Ethnicity and Stroke Study. Circulation 2007, 116:2157-2164.
8. Jones E.S., Owen E.P., Davidson J.S., Van Der Merwe L., Rayner B.L. The R563Q mutation of the epithelial sodium channel beta-subunit is associated with hypertension. Cardiovasc J Afr 2010, 21:1-4.
9. Rayner B., Jones E., Owen T. The prevalence and relationship to hypertension of the R563Q mutation of the epithelial sodium channel in Southern Africa. Cardiovasc J Afr 2011, 22:S21.
10. Rayner B.L., Owen E.P., King J.A., et al. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. J Hypertens 2003, 21:921-926.
11. Baker E.H., Duggal A., Dong Y., et al. Amiloride, a specific drug for hypertension in black people with T594M variant?. Hypertension 2002, 40:13-17.
12. Tapolyai M., Uysal A., Dossabhoy N.R., et al. High prevalence of Liddle syndrome phenotype among hypertensive US Veterans in Northwest Louisiana. J Clin Hypertens (Greenwich) 2010, 12:856-860.
13. Grim C.E., Robinson M. Salt, slavery and survival-hypertension in the African diaspora. Epidemiology 2003, 14:120-122.
14. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009, 94:3623-3630.
15. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
16. Russell R.P., Masi A.T. The prevalence of adrenal cortical hyperplasia at autopsy and its association with hypertension. Ann Intern Med 1970, 73:195-205.
17. Kidambi S., Kotchen J.M., Grim C.E., et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007, 49:704-711.
18. Franse L.V., Pahor M., Di B.M., et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000, 35:1025-1030.
19. Giacchetti G., Ronconi V., Turchi F., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007, 25:177-186.
20. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
21. Brown N.J. Aldosterone and vascular inflammation. Hypertension 2008, 51:161-167.
22. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318.
23. Neves M.F., Amiri F., Virdis A., Diep Q.N., Schiffrin E.L. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005, 83:999-1006.
24. Montezano A.C., Callera G.E., Yogi A., et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008, 28:1511-1518.
25. Leibovitz E., Ebrahimian T., Paradis P., Schiffrin E.L. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens 2009, 27:2192-2200.
26. Keidar S., Hayek T., Kaplan M., et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41:955-963.
27. Strawn W.B. Eplerenone antagonizes atherosclerosis, but what is the agonist?. Hypertension 2005, 46:1093-1094.
28. Takai S., Jin D., Muramatsu M., et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46:1135-1139.
29. Suzuki J., Iwai M., Mogi M., et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006, 26:917-921.
30. Imanishi T., Ikejima H., Tsujioka H., et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008, 51:734-741.
31. Savoia C., Touyz R.M., Amiri F., Schiffrin E.L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432-439.
32. Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., Feldman R.D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108:2400-2406.
33. Gros R., Ding Q., Armstrong S., et al. Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am. J Physiol Cell Physiol 2007, 292:C788-C794.
34. Feldman R.D., Gros R. Rapid vascular effects of steroids-a question of balance?. Can J Cardiol 2010, 26(suppl A):22A-26A.
35. Scheffers I.J., Kroon A.A., Schmidli J., et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010, 56:1254-1258.
36. Esler M.D., Krum H., Sobotka P.A., et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
37. Spence J.D. Physiologic tailoring of therapy for resistant hypertension: 20-year experience with stimulated renin profiling. Am J Hypertens 1999, 12:1077-1083.
38. Egan B.M., Basile J.N., Rehman S.U., et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009, 22:792-801.
39. Clark D., Ahmed M.I., Calhoun D.A. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012, 28:318-325.
40. de Rita O., Hackam D.G., Spence J. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012.
41. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995, 9:145-149.
42. Athyros V.G., Mikhailidis D.P., Kakafika A.I., Tziomalos K., Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother 2007, 8:529-535.
43. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
44. Heshka J., Ruzicka M., Hiremath S., McCormick B.B. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J Am Soc Hypertens 2010, 4:295-301.
45. de Gasparo M., Joss U., Ramjoue H.P., et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650-656.
46. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.